|
ZNF12 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.15130000036368E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.91369999963587E-07 |
| Normal-vs-Stage2 |
6.743500E-03 |
| Normal-vs-Stage3 |
8.54210000511557E-08 |
| Normal-vs-Stage4 |
3.01420000070607E-08 |
| Stage1-vs-Stage2 |
1.204800E-01 |
| Stage1-vs-Stage3 |
2.234200E-01 |
| Stage1-vs-Stage4 |
8.180300E-02 |
| Stage2-vs-Stage3 |
2.400100E-02 |
| Stage2-vs-Stage4 |
1.365860E-02 |
| Stage3-vs-Stage4 |
4.964000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.07230000048853E-07 |
| Normal-vs-AfricanAmerican |
9.560500E-04 |
| Normal-vs-Asian |
1.16959999996169E-06 |
| Caucasian-vs-AfricanAmerican |
9.701000E-01 |
| Caucasian-vs-Asian |
8.598000E-01 |
| AfricanAmerican-vs-Asian |
9.552200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.3435999996213E-07 |
| Normal-vs-Female |
1.54520000017477E-07 |
| Male-vs-Female |
4.442400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.59459999987877E-07 |
| Normal-vs-Age(41-60Yrs) |
1.10500000261027E-08 |
| Normal-vs-Age(61-80Yrs) |
3.87139999946662E-07 |
| Normal-vs-Age(81-100Yrs) |
1.040020E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.057400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.129600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.398400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.985800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.491000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.111000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.436000E-03 |
| Classical-VS-Follicular |
9.727400E-01 |
| Classical-VS-Other |
5.536800E-01 |
| Classical-VS-Normal |
3.17100000002402E-06 |
| Tall-VS-Follicular |
7.935800E-03 |
| Tall-VS-Other |
4.164400E-01 |
| Tall-VS-Normal |
7.9863999857821E-09 |
| Follicular-VS-Other |
6.062400E-01 |
| Follicular-VS-Normal |
1.75520999999845E-05 |
| Other-VS-Normal |
2.402300E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.52999999839076E-08 |
| Normal-vs-N1 |
4.25630000133737E-08 |
| N0-vs-N1 |
9.887700E-02 |
|
|
